June 06, 2018
1 min read
Save

Patients satisfied with Juvéderm Voluma XC for correction of infraorbital hollows

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Patients treated with Juvéderm Voluma XC to correct infraorbital hollows reported high satisfaction rates and experienced low rates of adverse events, according to a study.

A retrospective observational study evaluated the patient satisfaction of 101 patients who received cosmetic injection of Juvéderm Voluma XC (Allergan) at the Buckingham Center for Facial Plastic Surgery, Austin, Texas, between February 2016 and March 2017.

Patients were sent the FACE-Q Satisfaction with Eyes and FACE-Q Satisfaction with Decision surveys after treatment; 41 patients and 42 patients, respectively, completed the surveys.

Most respondents said they were “definitely satisfied” or “somewhat satisfied” with the outcome of treatment, with a mean overall satisfaction score of 71.1% for those who answered the Satisfaction with Eyes survey. The overall score regarding the decision to undergo treatment was 65.6% for those who answered the Satisfaction with Decision survey.

Twelve patients experienced adverse events, with three patients experiencing more than one. Adverse events included bruising, swelling and contour irregularity. One patient experienced the Tyndall effect, and three patients developed diffuse edema of the infraorbital area.

“Voluma’s higher G [greater firmness], compared with other Juvéderm products, allows it to maintain its shape and makes it more resistant to spreading then those fillers on the lowest end of the G spectrum,” the study authors wrote. “Its high patient satisfaction profile and a similar safety profile among other soft-tissue fillers make it an excellent adjunct in the plastic surgeon’s armamentarium.” – by Rebecca L. Forand

 

Disclosures: The authors report no relevant financial disclosures.